MX2023007918A - Uso de un inhibidor de kras g12c en el tratamiento de canceres. - Google Patents
Uso de un inhibidor de kras g12c en el tratamiento de canceres.Info
- Publication number
- MX2023007918A MX2023007918A MX2023007918A MX2023007918A MX2023007918A MX 2023007918 A MX2023007918 A MX 2023007918A MX 2023007918 A MX2023007918 A MX 2023007918A MX 2023007918 A MX2023007918 A MX 2023007918A MX 2023007918 A MX2023007918 A MX 2023007918A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- inhibitor
- cancer
- kras
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135449P | 2021-01-08 | 2021-01-08 | |
| US202163189625P | 2021-05-17 | 2021-05-17 | |
| PCT/US2022/011673 WO2022150628A1 (en) | 2021-01-08 | 2022-01-07 | Use of a kras g12c inhibitor in treating cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007918A true MX2023007918A (es) | 2023-07-13 |
Family
ID=80222156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007918A MX2023007918A (es) | 2021-01-08 | 2022-01-07 | Uso de un inhibidor de kras g12c en el tratamiento de canceres. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240091230A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4274579A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024502446A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022205969A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3206523A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023007918A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI906448B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022150628A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA127968C2 (uk) | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| EP3738593A1 (en) * | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| EP3972973A1 (en) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Solid state forms |
-
2022
- 2022-01-07 WO PCT/US2022/011673 patent/WO2022150628A1/en not_active Ceased
- 2022-01-07 MX MX2023007918A patent/MX2023007918A/es unknown
- 2022-01-07 TW TW111100657A patent/TWI906448B/zh active
- 2022-01-07 EP EP22703115.0A patent/EP4274579A1/en not_active Withdrawn
- 2022-01-07 US US18/270,581 patent/US20240091230A1/en active Pending
- 2022-01-07 CA CA3206523A patent/CA3206523A1/en active Pending
- 2022-01-07 JP JP2023541058A patent/JP2024502446A/ja active Pending
- 2022-01-07 AU AU2022205969A patent/AU2022205969A1/en active Pending
- 2022-01-07 EP EP25206294.8A patent/EP4650006A3/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022150628A1 (en) | 2022-07-14 |
| TWI906448B (zh) | 2025-12-01 |
| EP4650006A3 (en) | 2026-01-14 |
| EP4274579A1 (en) | 2023-11-15 |
| US20240091230A1 (en) | 2024-03-21 |
| AU2022205969A1 (en) | 2023-07-06 |
| EP4650006A2 (en) | 2025-11-19 |
| JP2024502446A (ja) | 2024-01-19 |
| AU2022205969A9 (en) | 2024-02-08 |
| TW202241442A (zh) | 2022-11-01 |
| CA3206523A1 (en) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001721A1 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer | |
| CO2021009882A2 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer | |
| CO2021017981A2 (es) | Inhibidores heterobicíclicos de mat2a y métodos de uso para el tratamiento del cáncer | |
| AR123996A2 (es) | Compuestos tricíclicos novedosos como agentes antineoplásicos | |
| MX2021003843A (es) | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| JOP20190254A1 (ar) | مركبات مضادة للأورام | |
| EA202190442A1 (ru) | СОЕДИНЕНИЯ 1H-ПИРАЗОЛО[4,3-d]ПИРИМИДИНА В КАЧЕСТВЕ АГОНИСТОВ TOLL-ПОДОБНОГО РЕЦЕПТОРА 7 (TLR7), СПОСОБЫ И ИХ ПРИМЕНЕНИЯ | |
| PE20141381A1 (es) | Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer | |
| CL2013003160A1 (es) | Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros. | |
| MX385562B (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2. | |
| CY1114608T1 (el) | Θεραπειες συνδυασμου που περιλαμβανουν κινοξαλινη αναστολεα pι3k αλφα για χρηση στην θεραπεια του καρκινου | |
| ECSP099724A (es) | Uso de inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cáncer | |
| CL2008001743A1 (es) | Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende. | |
| CR20130247A (es) | Compuestos tricíclicos de la pi3k y métodos de uso | |
| EA201490472A1 (ru) | Комбинированная терапия рака hsp90-ингибитором и антиметаболитом | |
| DOP2011000129A (es) | 1h-imidazol-2-il-piperidin-1-il como inhibidores de cinasa akt y p70 s6 | |
| MX2019007276A (es) | Composiciones y métodos para mejora o aumento de la producción de ifn tipo i. | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| MX2022006500A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
| UY28255A1 (es) | Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger | |
| EP4650006A3 (en) | Use of a kras g12c inhibitor in treating cancers | |
| MX389800B (es) | Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer | |
| MX2019009356A (es) | Sulfinilpiridinas y su uso en el tratamiento del cancer. | |
| MX391999B (es) | Piridinas y su uso en el tratamiento del cáncer. |